Towa Pharmaceutical (4553) Fundamentals 2026 — P/E 39.4x, Revenue Analysis | SniperIQ
Towa Pharmaceutical (4553) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥207.0B, trading at ¥4205.00 on the JPX. This SniperIQ fundamentals page covers Towa Pharmaceutical's valuation (P/E 39.4x, P/B 1.2x), profitability (net margin 1.9%), revenue (¥273.7B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Towa Pharmaceutical's market cap?
Towa Pharmaceutical (4553) has a market capitalization of approximately ¥207.0B, trading at ¥4205.00 on the JPX. Market cap moves with the live share price.
What is Towa Pharmaceutical's P/E ratio?
Towa Pharmaceutical's trailing twelve-month P/E ratio is 39.4x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Towa Pharmaceutical?
Towa Pharmaceutical runs a net profit margin of 1.9%, a gross margin of 36.2%, and an operating margin of 8.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Towa Pharmaceutical generate?
Towa Pharmaceutical reported revenue of ¥273.7B for fiscal year 2026, with net income of ¥5.3B and earnings per share (EPS) of 106.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Towa Pharmaceutical pay a dividend?
Towa Pharmaceutical offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Towa Pharmaceutical financially healthy?
Towa Pharmaceutical carries a debt-to-equity ratio of 1.27x and a current ratio of 2.76x, with a market beta of -0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Towa Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Towa Pharmaceutical (4553) the key facts are: market cap ¥207.0B, P/E 39.4x, revenue ¥273.7B, 52-week range 2764-4490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Towa Pharmaceutical's full fundamentals live
Get Towa Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.